Visitors Now:
Total Visits:
Total Stories:
Profile image
Story Views

Now:
Last Hour:
Last 24 Hours:
Total:

Hematological Malignancies Therapeutic Market – Technology & Market Analysis

Thursday, December 1, 2016 5:06
% of readers think this story is Fact. Add your two cents.

(Before It's News)

Hematological Malignancies Market analysis is provided for global market including development trends by regions, competitive analysis of the Hematological Malignancies market. Hematological Malignancies Industry report focuses on the major drivers and restraints for the key players.

“Hematological Malignancies: Multiple Myeloma (Mm) – Early and Robust Diagnosis Along With New Treatment Options Can Have Considerable Impact on Management of the Disease” report speaks about the manufacturing process. The process is analysed thoroughly with respect four points Manufacturers, regional analysis, Segment by Type and Segment by Applications and the actual process of whole Hematological Malignancies industry.

Browse More Information of Hematological Malignancies Market Research Report @http://www.absolutereports.com/10437984 

Over the past decade, Proteasome inhibitor and the immunomodulatory drugs have become the cornerstone of treatment for pts with Multiple Myeloma (MM) resulting in improved survival. However, eventually all pts relapse and use of modern diagnosis will enable risk stratification to help distinguish pts along the spectrum of the condition. This can aid in the selection of new treatment options for Relapsed/ Refractory Multiple Myeloma (RRMM) to further improve survival and quality of life of each patient. Two new drugs have successfully fulfilled this need – POMALYST/ IMNOVID (pomalidomide – POM, Celgene, approved) and Kyprolis (carfilzomib-CFZ, Amgen/ Ono Pharma – JP, approved). While novel targets address unmet need, the pertinent Question remains – is there a need for further improvement? What should be the diagnosis criteria and/or novel imaging / diagnostic tools that can further stratify a pts’ risk profile? 

Ask Sample PDF @ http://www.absolutereports.com/enquiry/request-sample/10437984 
In this report, we highlight the emerging new treatments in RRMM /NDMM, which includes combination of small molecules and biologics, and novel approach of molecular analysis of MM. This report also provides M&A deals in the diagnostic, cancer area along with growing market opportunities. Furthermore, the competitive landscape of NDMM and RRMM is also highlighted. The rivalry prevalent in the global onco-diagnostic and therapeutic MM market is quite fierce with numerous local and global players contenting for the market share. On the global diagnostic front, the key players are Roche, Abbott Diagnostics, and Illumina; and in Tx area, the key players are Celgene, Takeda pharma, Amgen, Novartis, and JNJ

While targeting unmet needs in the treatment of hematological malignancies/ cancer through innovative drug development strategies have witnessed favorable outcomes, the specific choice of the therapies is dependent on the identification of important genomic alterations in cancerous cells that allow for the tumor’s sub classification.

Ask for Discount @ http://www.absolutereports.com/enquiry/request-discount/10437984

Precision medicine approaches in myeloma require fast, robust, and practicable molecular diagnostic tools, and the current diagnostic standard iFISH (interphase fluorescence in situ hybridization) is unable to fulfill any of these criteria. Integration of Diagnostics into therapeutic products/ industry has potential to improve trial design, enhance safety profile, enhance therapeutic efficacy, accelerate trial outcome, and increase commercial success. However, there are few hurdles which are also associated with new model, such as understanding the diagnostic industry, complex trial execution, seeking a ‘right’ diagnostic partner, managing the co-development process, regulatory uncertainty around companion diagnostics and intellectual property issues. 

Two new drugs have successfully fulfilled this need – POMALYST/ IMNOVID (pomalidomide – POM, Celgene, approved) and Kyprolis (carfilzomib-CFZ, Amgen/ Ono Pharma – JP, approved). While novel targets address unmet need, the pertinent Question remains – is there a need for further improvement? What should be the diagnosis criteria and/or novel imaging / diagnostic tools that can further stratify a pts’ risk profile? 

Inquire More Details of Hematological Malignancies Market Research Report @ http://www.absolutereports.com/enquiry/pre-order-enquiry/10437984

Detailed TOC of Hematological Malignancies Market Research Report:

1. Executive Summary
2. Disease Overview, Diagnosis, and Current Treatment
2.1 Overview of Diagnostic tools for Multiple Myeloma
2.2 Diagnostic Criteria of Myeloma and Recent Amendment 
2.3 Diagnostic Approaches for Multiple Myeloma
2.3.1 Molecular pathogenesis of Myeloma 
2.3.2 Unmet Need 
2.3.3 New Diagnostics Perspective and Technologies
a ‘Companion’ Diagnostics (CDx)
b Genome-wide array
c RAN based technologies
d Next-Generation Sequencing (NGS) technology
3. Diagnostic Tools for Multiple Myeloma
3.1 Affymetrix GeneChip
3.2 SkylineDx MMprofiler
3.3 AgenaBio iPLEX Genotyping
3.4 Signal Genetics MyPRS
3.5 Cancer Genetics Genomic Products
3.6 Illumina NGS
3.7 NeoGenomics CLIA-certified Cancer Test
3.8 Exiqon microRNA PCR 
3.9 Regulus Therapeutics microRNA Marker
3.10 Rosetta Genomics Cancer Origin Test
3.11 Sequenta LymphoSIGHT Platform
4. M&A Deals and Market Opportunity in Diagnostic Space
5. Current Therapies
5.1 Newly Diagnosed Multiple Myeloma (NDMM)
5.1.1 Competitive Landscape for NDMM
5.2 Relapsed and/or Refractory Multiple Myeloma (RRMM)
5.2.1 Competitive Landscape for RRMM
5.3 Approved Therapies
5.3.1 Revlimid
5.3.2 Velcade
5.3.1 Kyprolis
5.3.2 POMALYST
5.1 Data Comparison
5.4.1 Newly Diagnosed Multiple Myeloma (NDMM)
5.4.2 Relapsed and/or Refractory Multiple Myeloma (RRMM)
6. Novel Targets
6.1 Monoclonal Antibodies
6.1.1 Elotuzumab
6.1.2 Situximab
6.1.3 Daratumumab
6.1.4 MOR202
6.1.5 SAR650984
6.1.6 BI-505
6.1.7 BHQ880
6.1.8 CT-011
6.1.9 IPH2101/ Lirilumab
6.1.10 BMS-936564 (ulocuplumab)
6.2 Small Molecules
6.2.1 Panobinostat
6.2.2 Ixazomib (MLN9708)
6.2.3 Aplidin (plitidepsin)
6.2.4 ARRY-520 (filanesib)
6.2.5 Oprozomib
6.2.6 KPT-330 (selinexor)
6.2.7 SNS01-T
6.2.8 Ibrutinib
6.2.9 Ricolinostat
6.2.10 Afuresertib
6.2.11 KW-2478
6.2.12 BT-062
7. Clinical Milestones
9. Launch Timeline and Commercial Opportunity of Late-Stage Pipeline
10. M&A/ Licensing Deals and Unpartnered Product Opportunities 

No. of Report pages: 82

Price of Report: $ 3000 (Single User Licence)

Purchase Report @ http://www.absolutereports.com/purchase/10437984

About Absolute Report:

Absolute Reports is an upscale platform to help key personnel in the business world in strategizing and taking visionary decisions based on facts and figures derived from in depth market research. We are one of the top report resellers in the market, dedicated towards bringing you an ingenious concoction of data parameters.

Contact–

Mr. Ameya Pingaley

Absolute Reports

+1-408 520 9750

Email – sales@absolutereports.com

http://www.absolutereports.com

Report abuse

Comments

Your Comments
Question   Razz  Sad   Evil  Exclaim  Smile  Redface  Biggrin  Surprised  Eek   Confused   Cool  LOL   Mad   Twisted  Rolleyes   Wink  Idea  Arrow  Neutral  Cry   Mr. Green

Top Stories
Recent Stories

Register

Newsletter

Email this story
Email this story

If you really want to ban this commenter, please write down the reason:

If you really want to disable all recommended stories, click on OK button. After that, you will be redirect to your options page.